APOLLOMICS（冠科美博）宣布启动C-MET抑制剂APL-101的II期全球多中心临床试验SPARTA 评估不分肿瘤类型的各种MET失调；聚焦MET 14号外显子跳跃突变的非小细胞肺癌及有MET扩增和融合的肿瘤，包括非小细胞肺癌，多形性胶质母细胞瘤及其他肿瘤 中国杭州市和美国福斯特市报道, May 21, 2020 (GLOBE NEWSWIRE) -- Apollomics,...

Apollomics, Inc. Announces Initiation of SPARTA Phase 2 Clinical Trial for c-MET Inhibitor APL-101 - Trial will evaluate diverse MET dysregulations across broad tumor types - - Focus on non-small cell lung cancer with a mutation that leads to MET exon 14 skipping, and tumors with...

AzurRx BioPharma Announces Entry into Packaging, Labeling and Distribution Agreement with Creapharm Clinical Supplies for MS1819 Clinical Trial Drug Product NEW YORK, May 07, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies...

Sermonix Doses First Patient in Phase 2 Clinical Trial of Lasofoxifene for Targeted Precision Medicine Treatment of Women With ESR1 Mutations in Metastatic Breast Cancer COLUMBUS, Ohio, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female-specific oncology products in the...